The company expects to add around 300 jobs through the facility, which will support the development and commercialization of the company’s gene therapies.
Bluebird’s $2.8M gene therapy opens door to pricing questions
Slavitt to leave COVID-19 response team in June; Diplomats push Biden administration to donate vaccine abroad; Biogen’s experimental blindness therapy fails in mid-stage trial.
Five things for pharma marketers to know: Friday, December 4, 2020